Evaluation of the Sensitivity and Specificity of a Novel Quality of Life Tool to Assess the Treatment Satisfaction in Psoriasis Patients

CompletedOBSERVATIONAL
Enrollment

143

Participants

Timeline

Start Date

December 4, 2020

Primary Completion Date

May 10, 2022

Study Completion Date

March 13, 2023

Conditions
Psoriasis
Interventions
OTHER

DLQI and PSO-TARGET QoL grid

At inclusion visit, and after 3 and 12 months, the patient will fill a patient questionnaire containing DLQI and PSO-TARGET QoL grid

Trial Locations (27)

Unknown

Cliniques Universitaires Saint Luc - UCLouvain, Brussels

Private practice, Geel

Private practice, Genk

Private practice, Kalken

Centre Dermatologique du Roy, Lasne

Dermatology Maldegem, Maldegem

CHU Ambroise Paré, Mons

CHU UCL Namur - Sainte Elisabeth, Namur

Private practice, Namur

Private practice, Waregem

Chu de Rennes, Auray

Chru de Besancon - Hopital Jean Minjoz, Besançon

Polyclinique de Courlancy-Bezanes, Bezannes

Centre Hospitalier de Boulogne-sur-mer, Boulogne-sur-Mer

CHU de CAEN, Caen

Ch William Morey, Chalon-sur-Saône

Nouvel Hôpital Sud Francilien, Corbeil-Essonnes

Ch Annecy Genevois, Épagny

Hopital Jacques Monod, Montivilliers

Cide Azur, Nice

Ch Cote de Lumiere, Olonne-sur-Mer

Hopital Paris Saint-Joseph, Paris

Ch de Perpignan, Perpignan

CHU de Poitiers, Poitiers

Hôpital d'Instruction des armées SAINTE ANNE, Toulon

Hopital Larrey, Toulouse

CHRU de NANCY - BSM BRABOIS, Vandœuvre-lès-Nancy

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

LEO Pharma

INDUSTRY

lead

Clinact

OTHER

NCT04765332 - Evaluation of the Sensitivity and Specificity of a Novel Quality of Life Tool to Assess the Treatment Satisfaction in Psoriasis Patients | Biotech Hunter | Biotech Hunter